このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

A Comparison of Ropinirole Immediate Release With Ropinirole Prolonged Release in Patients With Advanced Parkinson's

2017年8月21日 更新者：GlaxoSmithKline

A Randomised, Double-Blind, Double-Dummy, Parallel Group Comparison of 24 Weeks of Treatment With Ropinirole Immediate Release Tablets (REQUIP IR) or Ropinirole Prolonged Release Tablets (SK&F-101468) in Advanced Stage Parkinson's Disease Subjects Who Are Not Adequately Controlled on L-dopa.

This study was designed to compare the effectiveness and tolerability of a new prolonged release formulation of ropinirole with the currently marketed immediate release formulation which is prescribed in many countries. The new prolonged release formulation allows the drug to be taken once a day rather than three times a day. This study will also evaluate the side effects of the new prolonged release formulation of ropinirole

調査の概要

状態

完了

条件

介入・治療

研究の種類

介入

入学 (実際)

343

段階

  • フェーズ 3

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

  • イギリス
      • Chertsey、イギリス、KT16 0QA
        • GSK Investigational Site
      • Leigh、イギリス、WN7 1HS
        • GSK Investigational Site
      • Oxford、イギリス、OX3 9DU
        • GSK Investigational Site
    • Gloucestershire
      • Bristol、Gloucestershire、イギリス、BS16 1LE
        • GSK Investigational Site
    • Staffordshire
      • Stoke-on-Trent、Staffordshire、イギリス、ST4 7PA
        • GSK Investigational Site
  • イタリア
    • Abruzzo
      • Chieti Scalo、Abruzzo、イタリア、66013
        • GSK Investigational Site
    • Campania
      • Napoli、Campania、イタリア、80131
        • GSK Investigational Site
    • Lazio
      • Roma、Lazio、イタリア、00163
        • GSK Investigational Site
      • Roma、Lazio、イタリア、00148
        • GSK Investigational Site
    • Liguria
      • Genova、Liguria、イタリア、16132
        • GSK Investigational Site
    • Lombardia
      • Milano、Lombardia、イタリア、20142
        • GSK Investigational Site
      • Milano、Lombardia、イタリア、20133
        • GSK Investigational Site
      • Milano、Lombardia、イタリア、20126
        • GSK Investigational Site
    • Toscana
      • Grosseto、Toscana、イタリア、58100
        • GSK Investigational Site
      • Lido di Camaiore (Lucca)、Toscana、イタリア、55043
        • GSK Investigational Site
    • Veneto
      • Arcugnano (VI)、Veneto、イタリア、36057
        • GSK Investigational Site
  • ウクライナ
      • Kyiv、ウクライナ、01021
        • GSK Investigational Site
      • Kyiv、ウクライナ、04114
        • GSK Investigational Site
      • Poltava、ウクライナ、36024
        • GSK Investigational Site
      • Vinnitsa、ウクライナ、21005
        • GSK Investigational Site
  • カナダ
      • Québec、カナダ、G1R 3X5
        • GSK Investigational Site
    • Nova Scotia
      • Halifax、Nova Scotia、カナダ、B3J 3T1
        • GSK Investigational Site
    • Ontario
      • Ottawa、Ontario、カナダ、K1G 4G3
        • GSK Investigational Site
      • Toronto、Ontario、カナダ、M5T 2S8
        • GSK Investigational Site
      • Windsor、Ontario、カナダ、N8X 5A6
        • GSK Investigational Site
  • スペイン
      • Alcorcon (Madrid)、スペイン、28922
        • GSK Investigational Site
      • Barcelona、スペイン、08025
        • GSK Investigational Site
      • Madrid、スペイン、28007
        • GSK Investigational Site
      • San Sebastian、スペイン、20011
        • GSK Investigational Site
      • Sant Cugat del Valles (Barcelona)、スペイン、08190
        • GSK Investigational Site
      • Sevilla、スペイン、41013
        • GSK Investigational Site
      • Sevilla、スペイン、41071
        • GSK Investigational Site
  • チェコ
      • Brno、チェコ、625 00
        • GSK Investigational Site
      • Ostrava - Poruba、チェコ、708 52
        • GSK Investigational Site
      • Pardubice、チェコ、535 03
        • GSK Investigational Site
      • Praha 2、チェコ、120 00
        • GSK Investigational Site
      • Praha 5、チェコ、150 18
        • GSK Investigational Site
  • ドイツ
      • Berlin、ドイツ、10178
        • GSK Investigational Site
      • Berlin、ドイツ、12163
        • GSK Investigational Site
    • Bayern
      • Muenchen、Bayern、ドイツ、80331
        • GSK Investigational Site
      • Nuernberg、Bayern、ドイツ、90402
        • GSK Investigational Site
      • Unterhaching、Bayern、ドイツ、82008
        • GSK Investigational Site
    • Niedersachsen
      • Achim、Niedersachsen、ドイツ、28832
        • GSK Investigational Site
      • Hildesheim、Niedersachsen、ドイツ、31134
        • GSK Investigational Site
      • Westerstede、Niedersachsen、ドイツ、26655
        • GSK Investigational Site
    • Nordrhein-Westfalen
      • Bielefeld、Nordrhein-Westfalen、ドイツ、33647
        • GSK Investigational Site
    • Sachsen
      • Dresden、Sachsen、ドイツ、01097
        • GSK Investigational Site
    • Thueringen
      • Gera、Thueringen、ドイツ、07551
        • GSK Investigational Site
  • ハンガリー
      • Budapest、ハンガリー、1021
        • GSK Investigational Site
      • Budapest、ハンガリー、1135
        • GSK Investigational Site
      • Debrecen、ハンガリー、4012
        • GSK Investigational Site
      • Szeged、ハンガリー、6725
        • GSK Investigational Site
  • フランス
      • Aix en Provence、フランス、13616
        • GSK Investigational Site
      • Clermont Ferrand、フランス、63003
        • GSK Investigational Site
      • Dijon、フランス、21000
        • GSK Investigational Site
      • Lille Cedex、フランス、59037
        • GSK Investigational Site
      • Marseille、フランス、13385
        • GSK Investigational Site
      • Paris Cedex 14、フランス、75674
        • GSK Investigational Site
  • ブルガリア
      • Sofia、ブルガリア、1527
        • GSK Investigational Site
      • Sofia、ブルガリア、1113
        • GSK Investigational Site
      • Varna、ブルガリア、9010
        • GSK Investigational Site
  • ポーランド
      • Gdansk、ポーランド、80-299
        • GSK Investigational Site
      • Katowice、ポーランド、40-752
        • GSK Investigational Site
      • Krakow、ポーランド、31-530
        • GSK Investigational Site
      • Lublin、ポーランド、20-718
        • GSK Investigational Site
      • Poznan、ポーランド、61-298
        • GSK Investigational Site
      • Warsaw、ポーランド、02-097
        • GSK Investigational Site
  • ルーマニア
      • Bucharest、ルーマニア、11241
        • GSK Investigational Site
      • Cluj Napoca、ルーマニア、400012
        • GSK Investigational Site
  • ロシア連邦
      • Moscow、ロシア連邦、125101
        • GSK Investigational Site
      • Moscow、ロシア連邦、117049
        • GSK Investigational Site
      • Moscow、ロシア連邦、125367
        • GSK Investigational Site
      • Moscow、ロシア連邦、119881
        • GSK Investigational Site
      • Moscow、ロシア連邦、117593
        • GSK Investigational Site
      • St-Petersburg、ロシア連邦、194354
        • GSK Investigational Site
      • St. Petersburg、ロシア連邦、197022
        • GSK Investigational Site
      • St.-Petersburg、ロシア連邦、194291
        • GSK Investigational Site
  • 南アフリカ
      • Bloemfontein、南アフリカ、9301
        • GSK Investigational Site
      • Cape Town、南アフリカ、7925
        • GSK Investigational Site
      • Sunninghill、南アフリカ、2157
        • GSK Investigational Site
    • Gauteng
      • Pretoria、Gauteng、南アフリカ、0040
        • GSK Investigational Site

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

30年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion criteria:

  • Patients with a diagnosis of advanced idiopathic Parkinson's disease (according to modified Hoehn & Yahr criteria Stages II-IV) whose symptoms are not adequately controlled with L-dopa.

Exclusion criteria:

  • Patients with late stage advanced Parkinson's disease with incapacitating dyskinesias on a stable dose of L-dopa.
  • Current, or history of, (within the previous 3 months), significant and/or uncontrolled psychiatric, haematological, renal, hepatic, endocrinological, neurological, or cardiovascular disease or active malignancy.
  • Recent history of severe dizziness or fainting on standing.
  • Dementia, neurotic behaviour, crippling degenerative arthritis or limb amputations, or prior or current major psychosis.
  • Recent history or current evidence of drug abuse or alcoholism.
  • Use of a dopamine agonist within 4 weeks of starting the study.
  • Personal or family history of an allergic reaction to ropinirole.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか？

デザインの詳細

  • 主な目的：処理
  • 割り当て：ランダム化
  • 介入モデル：並列代入

この研究は何を測定していますか？

主要な結果の測定

結果測定
メジャーの説明
時間枠
Percentage of participants with at least a 20% maintained reduction in Baseline time spent "off" at Week 24 last observation carried forward (LOCF)
時間枠：Baseline (Week 0) and Week 24
Diary cards completed by the participants was used to assess the duration of "off" and "on" periods. During the treatment period 2, 24 hour diary cards were completed by the participants (except for the Baseline period when four diary cards were completed). The participants completed diary cards on the same 2 days of each relevant week. Each 30 minute period was marked as either "off", "on" or asleep. Troublesome dyskinesias were involuntary twisting, turning movements which caused discomfort were also recorded. The general definition of "off" included a lack of mobility with or without additional features such as tremor or rigidity. The total number of hours spent both "off" and "on" or asleep were summed for the two (four for the Baseline Period) 24 hour diary cards and the amount of awake time spent "off" per 24 hour period was determined. Percentage of participants with at least a 20% maintained reduction in baseline time spent "off" at Week 24 were presented.
Baseline (Week 0) and Week 24

二次結果の測定

結果測定
メジャーの説明
時間枠
Mean change from Baseline in percentage awake time spent "off" at Week 24 LOCF
時間枠：Baseline (Week 0) and Week 24
Diary cards completed by the Participants was used to assess the duration of "off" and "on" periods. During the Treatment Period 2 24 hour diary cards were completed by the Participants (except for the Baseline Period when four diary cards were completed). The Participants completed diary cards on the same 2 days of each relevant week. Each 30 minute period was marked as either "off", "on" or asleep. Troublesome dyskinesias were involuntary twisting, turning movements which caused discomfort were also recorded. The general definition of "off" included a lack of mobility with or without additional features such as tremor or rigidity. The total number of hours spent both "off" and "on" or asleep were summed for the two (four for the Baseline Period) 24 hour diary cards and the amount of awake time spent "off" per 24 hour period was determined. Week 0 was the baseline and change from Baseline was calculated by subtracting the baseline values from the on-treatment values.
Baseline (Week 0) and Week 24
Number of participants with a score of 'much improved' or 'very much improved' on the clinical global impression-global improvement (CGI-I) scale at Week 24 LOCF
時間枠：Week 24
The CGI-I global improvement scale allows the investigator to rate the participant's total improvement from beginning the treatment (baseline). The scale was rated as 1-7, from 1: very much improved, 2: much improved, 3: minimally improved, 4: no change, 5: minimally worse, 6: much worse and 7: very much worse. CGI global improvement scale was assessed at Week 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 20, 24 (and at early withdrawal, if applicable. Higher score indicates worsening and lower score indicates very much improvement. A participant was considered as a CGI-I responder when he/she had a score of (1) Very Much Improved or (2) Much Improved.
Week 24
Mean change from baseline in the total motor score (part III) of the Unified Parkinson's Disease Rating Scale (UPDRS), with participants in an "on" state at Week 24 LOCF
時間枠：Baseline (Week 0) and Week 24
The UPDRS Part III assessed motor examination on 18-31 items. Participants receive a score of 0-4 points per item. The maximum total score is 108 points. A higher score indicates more severe PD symptoms and lower score indicates less severe PD symptoms. "On" state was where PD symptoms were well controlled by the drug. Week 0 was the Baseline and change from Baseline for an individual participant was calculated by subtracting the Baseline values from the on-treatment values. Mean change from Baseline in the total motor score with participants in an "on" state was reported.
Baseline (Week 0) and Week 24
Mean change from baseline in the total motor score (part III) of the UPDRS, with participants in an "off" state at Week 24 LOCF
時間枠：Baseline (Week 0) and Week 24
The UPDRS Part III assessed motor examination on 18-31 items. Participants receive a score of 0-4 points per item. The maximum total score is 108 points. A higher score indicates more severe PD symptoms and lower score indicates less severe PD symptoms. Week 0 was the baseline and change from Baseline for an individual participant was calculated by subtracting the baseline values from the on-treatment values. Mean change from baseline in the total motor score with participants in an "off" state was reported.
Baseline (Week 0) and Week 24
Mean change from baseline in the total Activities of daily living (ADL) score (part II) of the UPDRS, with participants in an "on" state at Week 24 LOCF
時間枠：Baseline (Week 0) and Week 24
This component included items 5-17 of the UPDRS was evaluated by calculating the total score for the 13 items. Participants receive a score of 0-4 points per item and had a value ranging from 0 to 52. The maximum total score was 52. The total ADL Score of the UPDRS ranged from 0 to 52, where 0=normal/no symptoms and 52=worst possible case. Participants recorded responses in both "on" and "off" states at each visit due to the nature of questionnaire which generated ADL score at each visit. A higher score indicates more severe PD symptoms. "On" state was where PD symptoms were well controlled by the drug. Week 0 was the Baseline and change from Baseline for an individual participant was calculated by subtracting the baseline values from the on-treatment values for each state separately.
Baseline (Week 0) and Week 24
Mean change from baseline in the total ADL score (part II) of the UPDRS, with participants in an "off" state at Week 24 LOCF
時間枠：Baseline (Week 0) and Week 24
This component included items 5-17 of the UPDRS was evaluated by calculating the total score for the 13 items. Participants receive a score of 0-4 points per item and had a value ranging from 0 to 52. The maximum total score was 52. The total ADL Score of the UPDRS ranged from 0 to 52, where 0=normal/no symptoms and 52=worst possible case. Participants recorded responses in both "on" and "off" states at each visit due to the nature of questionnaire which generated ADL score at each visit. A higher score indicates more severe PD symptoms. "Off" state was where PD symptoms were not adequately controlled by the drug. Week 0 was the baseline and change from Baseline for an individual participant was calculated by subtracting the baseline values from the on-treatment values for each state separately.
Baseline (Week 0) and Week 24
Mean change from baseline in the total score (parts I-III) of the UPDRS, with participants in an "on" state at Week 24 LOCF
時間枠：Baseline (Week 0) and Week 24
The total UPDRS score was calculated by the sum of the values for each component (Part I + Part II + Part III) as determined by the physician. The UPDRS Part I scored mentation, behavior and mood and scores ranged from 0-16. The UPDRS Part II was the ADL and score ranged from 0-52. The UPDRS Part III was the Motor Examination (Total Motor Score )and scores ranged from 0-108. The total UPDRS (Part I + II + III) score ranged from 0-176 with the higher score indicating the worse condition. Tests were performed when the participant was in the "on" state of Parkinson's. Baseline was defined as Week 0 assesment. The change from Baseline was calculated by subtracting the Baseline values from the individual post-randomization values.
Baseline (Week 0) and Week 24
Mean change from baseline in the total score (parts I-III) of the UPDRS, with participants in an "off" state at Week 24 LOCF
時間枠：Baseline (Week 0) and Week 24
The total UPDRS score was calculated by the sum of the values for each component (Part I + Part II + Part III) as determined by the physician. The UPDRS Part I scored mentation, behavior and mood and scores ranged from 0-16. The UPDRS Part II was the ADL and score ranged from 0-52. The UPDRS Part III was the Motor Examination (Total Motor Score)and scores ranged from 0-108. The total UPDRS (Part I + II + III) score ranged from 0-176 with the higher score indicating the worse condition. Tests were performed when the participant was in the "off" state of Parkinson's. Baseline was defined as Week 0 assessment. The change from Baseline was calculated by subtracting the Baseline values from the individual post-randomization values.
Baseline (Week 0) and Week 24
Mean change from baseline to Week 24 LOCF in the thermometer score of the Euro-Qol 5D (EQ-5D)
時間枠：Baseline (Week 0) and Week 24
The EQ-5D was a standardized, participant-administered instrument which produced a simple descriptive profile (thermometer) and a single index value (utility) of a participant's current health status. Thermometer was a 20-cm Visual Analogue Scale (VAS) anchored at 0: worse imaginable health state and 100: best imaginable health state. Participants were required to indicate how good or bad was their health by marking a line on the scale. The point at which the line crossed the thermometer was taken as the score. Week 0 was the baseline and change from Baseline was calculated by subtracting the baseline values from the on-treatment values.
Baseline (Week 0) and Week 24
Mean change from baseline to Week 24 LOCF in the utility score of the EQ-5D
時間枠：Baseline (Week 0) and Week 24
The EQ-5D was a standardized, participant-administered instrument which produced a simple descriptive profile (thermometer) and a single index value (utility) of a participant's current health status. Utility score was computed from 5 dimensions of health: (mobility, self-care, usual activities, pain/discomfort, anxiety /depression). Each dimension comprised 3 levels (some, moderate, extreme problems), and generated a total of 243 theoretically possible health states. The Utility score was combined scores from 5 dimensions, which valued between -0.594 (representing the worse possible health) and 1 (representing the perfect health). Week 0 was the baseline and change from Baseline was calculated by subtracting the baseline values from the on-treatment values.
Baseline (Week 0) and Week 24
Mean change from Baseline in the total score of the Parkinson's Disease Sleep Scale (PDSS) at Week 24 LOCF
時間枠：Baseline (Week 0) and Week 24
The PDSS comprised of a series of 15 VAS addressing commonly reported symptoms associated with sleep disturbance in PD. The participant or caregiver completed the scale based on their experiences in the past week. Scores for each item ranged from 0 (representing the most severe) to 10 (the least severe). The maximum score for the PDSS was 150 (participant was free of all symptoms). Week 0 was the baseline and change from Baseline was calculated by subtracting the baseline values from the on-treatment values.
Baseline (Week 0) and Week 24
Mean change from Baseline in the total movement severity score of the abnormal involuntary movement scale (AIMS), with participants in an "on" state at Week 24 LOCF
時間枠：Baseline (Week 0) and Week 24
The AIMS was a 12 item, investigator performed assessment of facial and oral movements, extremity movements, trunk movements, global judgments and dental status according to predefined criteria. Items 1-10 were rated on a 5 point severity scale with 0: none to 4: severe. Items 11 and 12 were yes or no items. The AIMS total movement severity score was obtained by summing together the responses to the first seven items and ranged from 0 to 28, with higher scores representing more severe involuntary movement. The AIMS was assessed at Week 0, 12, 24. Week 0 was the baseline and change from Baseline was calculated by subtracting the baseline values from the on-treatment values.
Baseline (Week 0) and Week 24
Percentage of participants requiring re-instatement of L-dopa
時間枠：Week 24
Participants were defined as having a re-instatement of L-dopa, if at any point during the on-treatment phase (excluding down-titration), their dose of L-dopa was increased, up to, or above their baseline level. Percentage of participants requiring reinstatement of L-dopa was reported at Week 24.
Week 24
Mean change from baseline in the dose of L-dopa at Week 24 LOCF
時間枠：Baseline (Week 0) and Week 24
The start and stop dates of L-Dopa medication were used to determine the dose being taken on a specific date or at an assessment. The dose recorded on the actual date of assessment was used when reporting the corresponding dose. The total daily dose of L-dopa (mg) was calculated as Unit dose per tablet (mg) * Daily Frequency * No of Tablets per administration. Mean change from baseline in the dose of L-dopa at Week 24 was reported. Week 0 was the baseline and change from Baseline was calculated by subtracting the baseline values from the on-treatment values.
Baseline (Week 0) and Week 24
Incidence of all adverse events (AE) and serious adverse events (SAE)
時間枠：Up to Week 27
Data for number of participants who presented one or more adverse events (serious or non serious) was reported. An AE was defined as any untoward medical occurrence (MO) in a participant temporally associated with the use of a medicinal product (MP), whether or not considered related to the MP and can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with its use. The SAE was any untoward MO that, at any dose, results in death, life threatening, persistent or significant disability/incapacity, results in or prolongs inpatient hospitalization, congenital abnormality or birth defect, that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the participant or may require medical or surgical intervention to prevent one of the other outcomes listed in this definition.
Up to Week 27
Number of participants who were unable to titrate weekly during the 4 week forced up titration due to poor tolerability
時間枠：Up to Week 24
There was no specific question in the CRF to capture the reason why participants were unable to titrate weekly during this period, the data on the reason for withdrawal in the CRF was thus evaluated in those participants who withdrew during the forced titration period. Data for the number of participants withdrawn (Yes/No) is presented.
Up to Week 24

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

GlaxoSmithKline

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2006年6月20日

一次修了 (実際)

2007年8月29日

研究の完了 (実際)

2007年8月29日

試験登録日

最初に提出

2006年5月26日

QC基準を満たした最初の提出物

2006年5月26日

最初の投稿 (見積もり)

2006年5月29日

学習記録の更新

投稿された最後の更新 (実際)

2017年8月22日

QC基準を満たした最後の更新が送信されました

2017年8月21日

最終確認日

2017年8月1日

詳しくは

本研究に関する用語

キーワード

追加の関連 MeSH 用語

その他の研究ID番号

  • ROP105323

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

パーキンソン病の臨床試験

  • Adelphi Values LLC
    Blueprint Medicines Corporation
    完了
    全身性肥満細胞症の患者報告アウトカムアンケート
    肥満細胞性白血病 (MCL) | 攻撃的な全身性肥満細胞症 (ASM) | SM w Assoc Clonal Hema Non-mast Cell Lineage Disease (SM-AHNMD) | くすぶり全身性肥満細胞症 (SSM) | 無痛性全身性肥満細胞症 (ISM) ISM サブグループが完全に募集されました
    アメリカ

Ropinirole prolonged releaseの臨床試験

類似の治験を検索

スポンサーと協力者

医学的状態

薬物療法

CROs by country

CROs in Canada

条件

まれな病気

薬物療法

ダイエットサプリメント

スポンサー/協力者

場所

3
購読する